Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 1, Pages 240
Publisher
MDPI AG
Online
2020-12-29
DOI
10.3390/ijms22010240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors
- (2020) Rieko Oyama et al. Cancer Cell International
- Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
- (2020) Yuko Nishinaga et al. Cells
- Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck
- (2020) Alec J. Kacew et al. ORAL ONCOLOGY
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
- (2020) Andrea B Apolo et al. Journal for ImmunoTherapy of Cancer
- Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Takahiro Wakasaki et al. Cancers
- Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors
- (2020) Yasuhiro Maruoka et al. Cancers
- HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
- (2019) Giacomo Bregni et al. JAMA Oncology
- Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study
- (2019) Kuniko Sunami et al. CANCER SCIENCE
- Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
- (2019) David M. Cognetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Near-Infrared Photoimmunotherapy of Cancer
- (2019) Hisataka Kobayashi et al. ACCOUNTS OF CHEMICAL RESEARCH
- Tumour-associated neutrophils in patients with cancer
- (2019) Merav E. Shaul et al. Nature Reviews Clinical Oncology
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Khalil Saleh et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma
- (2019) Roberto Carmagnani Pestana et al. ORAL ONCOLOGY
- Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
- (2019) Petr Szturz et al. ORAL ONCOLOGY
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
- (2018) M Tahara et al. ANNALS OF ONCOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Implementation of “clinical sequencing” in cancer genome medicine in Japan
- (2018) Takashi Kohno CANCER SCIENCE
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
- (2018) Clara Montagut et al. JAMA Oncology
- Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)
- (2018) Kuniko Sunami et al. CANCER SCIENCE
- Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy
- (2017) Rogerio Castilho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
- (2017) Shinji Kohsaka et al. Science Translational Medicine
- Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
- (2016) Stefano Maria Magrini et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
- (2016) Kanwal Raghav et al. Oncotarget
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
- (2015) J. Guigay et al. ANNALS OF ONCOLOGY
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
- (2011) R. Hitt et al. ANNALS OF ONCOLOGY
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
- (2011) Makoto Mitsunaga et al. NATURE MEDICINE
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
- (2009) K. Muro et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now